Dermata Therapeutics, Inc. Common Stock
DRMAStock
$1.28−81.89%52W
Market Cap$5.23M
P/E—
Div yield—
Beta0.69
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-50.27%
Price vs S&P 500 (4W)10.40%
VGM Score32.83
Market Capitalization$5.23M
Earnings Surprise History
Q1 26-0.48est. -0.54
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DRMADermata Therapeutics, Inc. Common Stock | — | — | D | $1.28 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Dermata Therapeutics develops OTC dermatology treatments for acne, psoriasis, rosacea, and seborrheic dermatitis. The company is advancing a once-weekly acne treatment leveraging its proprietary Spongilla technology platform for enhanced delivery and patient compliance. Dermata plans to expand Spongilla's application across dermatologic and aesthetic markets, including intradermal delivery of botulinum toxin, providing multiple revenue opportunities.